

TORRENT PHARMACEUTICALS LIMITED

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2004

[Rs. in lacs except per share data]

PARTICULARS	THREE MONTHS ENDED ON		ACCOUNTING YEAR ENDED ON
	30-06-2004	30-06-2003	31-03-2004
Sales (net of Sales Tax collected) [see note 2]	13388	12592	47730
Less: Excise Duty collected	1322	1289	4742
Net Sales	12066	11303	42988
Other Operating Income	305	275	1319
Net Sales & Income from Operations	12371	11578	44307
Expenditure			
(Increase)/Decrease in Stock in Trade	(268)	554	(1043)
Consumption of Raw/Packing Material and Purchase of Traded Goods [see note 2]	4232	4119	17706
Staff Cost	1423	954	4074
Manufacturing & Other Expenses	1202	1001	5472
Selling Expenses	1405	1077	4873
Research & Development Expenses	1021	652	2948
Total Expenditure	9015	8357	34030
Operating Profit before Interest, Depreciation & Amortization and Tax	3356	3221	10277
Net Interest expense/(income)	14	(14)	(24)
Depreciation & Amortization	405	345	1569
Operating Profit before Tax	2937	2890	8732
Other Income	69	45	365
Profit before Tax and Exceptional Items	3006	2935	9097
Provision for Taxation			
Current Tax	476	763	2117
Deferred Tax	218	83	363
Short Provision of Tax of Earlier Years	-	-	40
	694	846	2520
Profit after Tax and before Exceptional Item	2312	2089	6577
Prior Period Adjustment	-	-	(4)
Exceptional Items (net)	-	-	(156)
Net Profit for the Period	2312	2089	6417
Paid-up Equity Share Capital [Face Value Rs.10]	2116	2110	2116
Reserves excluding revaluation reserves	-	-	28603
Basic & Diluted EPS for the period	10.93	9.87	30.33
Non-Promoter shareholding			
Number of shares	5486958	5487758	5486958
Percentage of shareholding	25.93%	25.93%	25.93%

NOTES:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 17-Aug-04. There is no qualification in the Auditors Report on this statement of financial results.
- 2 a Inter unit transfers of manufactured bulk drugs Rs. 386 lacs for the comparative quarter (Rs. 1751 lacs for the previous year) have been excluded from the sales and material costs of those periods.
b The figures for the comparative periods have been regrouped to render them comparable with the figures for the current period.
- 3 This statement of financial results has been prepared by applying the same accounting policies as were applied in the annual financial statements for the previous year.
- 4 The Company operates in a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Quarter Ended			Year Ended
	30-Jun-04	30-Jun-03	Growth (%)	31-Mar-04
Domestic Formulations	8591	7762	11%	28475
Exports	1683	1011	66%	5171
Consolidated Exports*	2549	1221	109%	6683
Contract Manufacture	1778	2432	(27%)	9183
Others	14	98	-	159
Total	12066	11303	7%	42988
Consolidated Sales*	12932	11513	12%	44500

* Indicates sales of the Company and its subsidiaries consolidated as per Accounting Standard 21 Consolidated Financial Statements. These figures are not audited for the current and comparative quarter.

- 5 The Company has entered into a Licence Agreement with Novartis Pharma AG, a leading international pharma company based at Switzerland granting global rights of its patented AGE (Advanced Glycosylation Endproducts) Breaker compound during the last week of July 04. It will entitle the Company to receive an upfront payment of USD 3 million. The agreement also envisages a long term arrangement involving subsequent milestone payments as the molecule passes through various phases of clinical development, regulatory approvals and ultimate commercialization. Further the Company would also be entitled to royalties linked with global sales.
- 6 Information relating to investor complaints as required by clause 41 of listing agreement for the quarter ended 30-Jun-04 is as follows:
Un-disposed complaints as of 1-Apr-04 Nil
Complaints received during the quarter 14
Complaints disposed of during the quarter 14
Un-disposed complaints as of 30-Jun-04 Nil

For TORRENT PHARMACEUTICALS LIMITED

Place Ahmedabad
Date 17-Aug-04

Sd/-
SAMIR MEHTA
Managing Director

.... Visit us at www.torrentpharma.com....